Cargando…
A four-microRNA classifier as a novel prognostic marker for tumor recurrence in stage II colon cancer
About 20 percent of TNM-stage II colon cancer patients who are treated by surgical resection develop recurrence, and adjuvant chemotherapy in this group is still debated among researchers and clinicians. Currently, adverse histopathological and clinical factors are used to select patients for adjuva...
Autores principales: | Jacob, Havjin, Stanisavljevic, Luka, Storli, Kristian Eeg, Hestetun, Kjersti E., Dahl, Olav, Myklebust, Mette P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906690/ https://www.ncbi.nlm.nih.gov/pubmed/29670141 http://dx.doi.org/10.1038/s41598-018-24519-4 |
Ejemplares similares
-
Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer
por: Jacob, Havjin, et al.
Publicado: (2017) -
Stage-dependent prognostic shift in mismatch repair-deficient tumors: Assessing patient outcomes in stage II and III colon cancer
por: Hestetun, Kjersti Elvestad, et al.
Publicado: (2022) -
Laparoscopic complete mesocolic excisions for colonic cancer in the last decade: Five-year survival in a single centre
por: Storli, Kristian Eeg, et al.
Publicado: (2017) -
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population‐based series and a randomized phase III study on adjuvant chemotherapy
por: Boye, Kjetil, et al.
Publicado: (2016) -
Long-Term Outcome in a Phase II Study of Regional Hyperthermia Added to Preoperative Radiochemotherapy in Locally Advanced and Recurrent Rectal Adenocarcinomas
por: Schem, Baard-Christian, et al.
Publicado: (2022)